医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ResearchDx, the Leading Contract Diagnostics Organization, Receives a Strategic Partner Award From WuXi AppTec

2014年04月24日 AM04:00
このエントリーをはてなブックマークに追加


 

IRVINE, Calif.

ResearchDx, LLC of Irvine, California announced today that it has received a 2013 Strategic Partner Award from WuXi AppTec, Ltd. The award was given in recognition of the outstanding consulting and personnel services provided to the WuXi AppTec Genome Center Clinical Laboratory in attaining Clinical Laboratory Improvement Amendments (CLIA) certification from the Centers for Medicare and Medicaid Services of the U.S. Department of Health and Human Services. WuXi’s clinical laboratory is the only CLIA-certified clinical laboratory in China.

“We are delighted to receive the Strategic Partner Award from WuXi AppTec, a global pharmaceutical, biopharmaceutical, and medical device R&D services company, and are proud to partner with them. Our mutual success is based on a shared commitment to provide services of the highest quality to clinical laboratory clients,” said Dr. Philip Cotter, Principal and Co-Founder of ResearchDx.

The Consulting Services Division of ResearchDx provides comprehensive Clinical Laboratory consulting services encompassing quality management systems; assay design, validation and implementation; and consulting for CLIA and International CLIA certification, State licensures, and Joint Commission International, College of American Pathologists, and ISO 15189 accreditations.

“The award is timely, as ResearchDx is increasingly working with international clients seeking accreditations for their Clinical Laboratories. ResearchDx offers its clients unparalleled experience in opening, licensing, and operating Clinical Laboratories, both in the U.S. and overseas,” said Dr. Mathew Moore, Principal and Co-Founder of ResearchDx.

ResearchDx is the leading Contract Diagnostics Organization serving the biopharmaceutical and diagnostic industries. The company provides comprehensive, integrated, and flexible services for the in vitro diagnostic development process. From initial assay conceptualization, discovery, optimization, and validation in a CAP/CLIA laboratory environment through a complete set of clinical research services and regulatory approval, ResearchDx offers solutions to meet customers’ complex needs in diagnostics development. ResearchDx’s primary service areas include assay research and development, clinical laboratory services, clinical research, diagnostic manufacturing, and consulting. Additional information is available at www.researchdx.com.

CONTACT

ResearchDx
Philip
D. Cotter
, PhD, FACMG, FFSc(RCPA)
866-225-9195 / 510-332-0477
pcotter@researchdx.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics
  • 武田呈报3期ALTA-1L试验结果,显示在晚期ALK+非小细胞肺癌一线治疗中,ALUNBRIG® (brigatinib)的颅内有效性优于克唑替尼
  • Philip Morris International Launches Next Generation of IQOS, the World’s Leading Heated Tobacco Product
  • PotNetwork Holdings, Inc.第三季度业绩创纪录,营收超过610万美元
  • ポットネットワーク・ホールディングスが610万ドルを超える収益で過去最高の第3四半期を終える